Health is a matter of fundamental importance in European societies, both as a human right in itself, and as a factor in a productive workforce and therefore a healthy economy. New health technologies promise improved quality of life for patients suffering from a range of diseases, and the potential for the prevention of incidence of disease in the future. At the same time, new health technologies pose significant challenges for governments, particularly in relation to ensuring the technologies are safe, effective, and provide appropriate value for (public) money.
To guard against the possible dangers arising from new health technologies, and to maximize the benefits, all European governments regulate their development, marketing, and public financing. In addition, several international institutions operating at European level, in particular the European Union, the Council of Europe, and the European Patent Office, have become involved in the regulation of new health technologies. They have done so both through traditional 'command and control' legal measures, and through other regulatory mechanisms, including guidelines, soft law, 'steering' through redistribution of resources, and private or quasi-private regulation.
This collection analyses European law and its relationships with new health technologies. It uses interdisciplinary insights, particularly from law but also drawing on regulation theory, and science and technology studies, to shed new light on some of the key defining features of the relationships and especially the roles of risk, rights, ethics, and markets. The collection explores the way in which European law's engagement with new health technologies is to be legitimized, and discusses the implications for biological or biomedical citizenship.
Rezensionen / Stimmen
This book is novel in focusing on the European regulatory environment pertaining to NHTs...The aim [of the 1st part of the book] appears to be rather to broaden the reader's horizons so as to be able to see the wider picture. Chapter 2 for example does this brilliantly, providing a sound overview of the potential influences of EU law on NHTs... Present[s] a number of well-selected examples of contemporary problems with European regulation of NHTs. Such examples are thought-provoking and serve to highlight the need for constant regulatory vigilance and willingness to reform in this area...Even a reader with familiarity of some or many aspects of NHT regulation will find something new and instructive in the various topics that have been chosen. The central topic of this book extremely relevant given the upcoming revision of the data protection directive and the medical device directives proposed by the European Commission. * Quinn, Common Market Law Review * This is an excellent collection that provides a rich overview of the ways in which European law shapes, and is shaped by, new health technologies and, arguably, offers a first step towards the constitution of the European Law of new health technologies as an emerging field of inquiry. Bringing together a vast range of technological developments, of disciplinary insights, and of conceptual questions, this will become a key resource for any scholar seeking to explore the relationship between health technologies and European law and policy, but also for those more broadly interested in the interface between law and technoscience. * E. Cloatre, Kent Law School *
Reihe
Sprache
Verlagsort
Zielgruppe
Für höhere Schule und Studium
Scholars and students of European law, regulation, and medical health and technology
Maße
Höhe: 240 mm
Breite: 162 mm
Dicke: 36 mm
Gewicht
ISBN-13
978-0-19-965921-0 (9780199659210)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Klassifikation
Mark Flear is a Lecturer in Law at Queen's University of Belfast. He is also a member of the Northern Ireland DNA Database Governance Board. His works include the forthcoming title The Biopolitics of EU Public Health Governance: Cancer, HIV/AIDS and Pandemics.
Anne-Maree Farrell is Associate Professor at the Faculty of Law, Monash University, Australia. Her research expertise lies broadly within the area of health law and policy, with a particular interest in the regulatory governance of human biological materials. Recent publications include The Politics of Blood: Ethics Innovation and the Regulation of Risk (2012) and Organ Shortage: Ethics Law and Pragmatism (co-edited with D. Price and M. Quigley, 2011).
Tamara Hervey is Jean Monnet Professor of EU Law at the University of Sheffield, UK. Her research and teaching interests are in the field of European Union social and constitutional law, in particular its application in health fields, social security and welfare. She works across disciplines, and considers law in the context of broader modes of regulation. She is interested in socio-legal theory and method, and legal research methodologies in general, in particular as applied to the law of the European Union. Her recent books include Health Law and the European Union (with J McHale, 2004), Health Systems Governance in Europe: The role of EU law and policy (with E Mossialos, G Permanand, and R Baeten, 2010), andResearch Methodologies in EU and International Law (with R Cryer, B Sokhi-Bulley, and A Bohm, 2011).
Therese Murphy is the Professor of Law and Critical Theory in the Faculty of Social Sciences at the University of ?Nottingham. Her work focuses on human rights law and practice, and her publications include
Civil Liberties Law: The Human Rights Act Era (2001), New Technologies and Human Rights (2009), and the forthcoming Health and Human Rights.
Herausgeber*in
, Lecturer in Law, Queen's University Belfast
, Associate Professor at the Faculty of Law, Monash University, Australia
, Jean Monnet Professor of European Union Law, University of Sheffield School of Law
, Professor of Law and Critical Theory, University of Nottingham
PART I: SETTING THE SCENE; PART II: LEGAL APPROACHES TO EUROPEAN LAW AND NEW HEALTH TECHNOLOGIES; PART III: REGULATORY THEORY, REGULATORY INNOVATION, EUROPEAN LAW AND NEW HEALTH TECHNOLOGIES; PART IV: NEW TECHNIQUES FOR RESEARCHING EUROPEAN LAW AND NEW HEALTH TECHNOLOGIES; PART V: BRINGING IT ALL TOGETHER
